bioRxivBiochemistryPreprint
Identification of low micromolar SARS-CoV-2 Mpro inhibitors from hits identified by in silico screens
G. G. Rossetti, M. Ossorio, S. Barriot, L. Tropia, V. S. Dionellis, C. Gorgulla, H. Arthanari, P. Mohr, R. Gamboni, T. D. Halazonetis
Abstract
Mpro, also known as 3CLpro, is the main protease of the SARS-CoV-2 coronavirus and, as such, is essential for the viral life cycle. Two studies have each screened and ranked in silico more than one billion chemical compounds in an effort to identify putative inhibitors of Mpro. More than five hundred of the seven thousand top-ranking hits were synthesized by an external supplier and examined with respect to their activity in two biochemical assays: a protease activity assay and a thermal shift assay. Two clusters of chemical compounds with Mpro inhibitory activity were identified. An additional five hundred molecules, analogues of the compounds in the two clusters described above, were also synthesized and characterized in vitro. The study of the analogues revealed that the compounds of the first cluster acted by denaturing Mpro and might denature other proteins as well. In contrast, the compounds of the second cluster targeted Mpro with much greater specificity and enhanced its melting temperature, consistent with the formation of stable Mpro-inhibitor complexes. The most active compounds of the second cluster exhibited IC50 values between 4 and 7 M and their chemical structure suggests that they could serve as leads for the development of potent Mpro inhibitors.
- assay: proteomics
- research focus: drug response / drug discovery
- research focus: perturbation response prediction
- approach: experimental assay
- approach: biophysical modeling
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Discovery of Semicarbazone and Thiosemicarbazone Analogs as Competitive SARS-CoV-2 Virus Main Protease (Mpro) Inhibitors
Luiza Valença Barreto, Estela Mariana Guimarães Lourenço, … Rafaela Salgado Ferreira·bioRxiv·Mar 12, 2026
- Identification of 14 Known Drugs as Inhibitors of the Main Protease of SARS-CoV-2
M. M. Ghahremanpour, J. Tirado-Rives, … W. L. Jorgensen·bioRxiv·Aug 28, 2020
- Structure-based identification of naphthoquinones and derivatives as novel inhibitors of main protease Mpro and papain-like protease PLpro of SARS-CoV-2
L. H. Santos, T. Kronenberger, … R. Ferreira·bioRxiv·Jan 5, 2022
- Discovery of Potent Pyrazoline-Based Covalent SARS-CoV-2 Main Protease Inhibitors
P. Moon, L. Boike, … D. K. Nomura·bioRxiv·Mar 5, 2022
- Ebselen, disulfiram, carmofur, PX-12, tideglusib, and shikonin are non-specific promiscuous SARS-CoV-2 main protease inhibitors
- Rational design of a new class of protease inhibitors for the potential treatment of coronavirus diseases
M. Westberg, Y. Su, … M. Lin·bioRxiv·Sep 15, 2020